In a research report issued today, J.P. Morgan analyst Cory Kasimov maintained a Neutral rating on shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN), after the company released its second-quarter earnings results, posting non-GAAP EPS of $2.89 that beat consensus estimates of $2.77 and JPM estimates of $2.74.
Kasimov observed, “This morning REGN printed another top- and bottom-line beat. In particular, Eylea boasted an impressive quarter with $655M in US sales (+21% Q/Q, +58% Y/Y), which prompted another bump to 2015 revenue guidance. In addition to Eylea, Regeneron tweaked several other guidance line items that should help bottom-line performance for the full year. There were incremental pipeline updates in the press release, most notably that the dupilumab Phase 3 trial for in atopic dermatitis has now been fully enrolled.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Cory Kasimov has a total average return of 13.3% and a 59.4% success rate. Kasimov is ranked #248 out of 3724 analysts.
Out of the 18 analysts polled by TipRanks, 12 rate Regeneron Pharmaceuticals stock a Buy, while 6 rate the stock a Hold. With a downside potential of 17%, the stock’s consensus target price stands at $491.60.